Zymeworks, Jazz agree to licensing deal for cancer drug
marketwatch.com
news
2022-10-19 12:38:08

Shares of Zymeworks Inc. ZYME, -2.43% gained 8.4% in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -0.41% for its cancer drug, zanidatamab, which is currently being tested as a treatment for some HER2-expressing cancers. Jazz will pay Zymeworks $50 million upfront. Including all regulatory and commercial milestone payments, the deal, which is expected to close before the end of the year, is worth up to a total $1.7 billion. Zymeworks' stock is down 66.
